Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy
The present study examines the role of advanced glycation end products (AGEs) as biomolecular biomarkers for proliferative diabetic retinopathy (PDR). A cross-sectional study with a total of 80 consecutive cases of type 2 diabetes mellitus (DM) was divided into no retinopathy (NoDR) (n = 20), non-pr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-06-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/IJO.IJO_2115_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849425441332396032 |
|---|---|
| author | Nibha Mishra Sandeep Saxena Rajendra K. Shukla Anshul Tiwari |
| author_facet | Nibha Mishra Sandeep Saxena Rajendra K. Shukla Anshul Tiwari |
| author_sort | Nibha Mishra |
| collection | DOAJ |
| description | The present study examines the role of advanced glycation end products (AGEs) as biomolecular biomarkers for proliferative diabetic retinopathy (PDR). A cross-sectional study with a total of 80 consecutive cases of type 2 diabetes mellitus (DM) was divided into no retinopathy (NoDR) (n = 20), non-proliferative diabetic retinopathy (NPDR) (n = 20), PDR (n = 20), and controls (n = 20). AGEs were assessed by assay of N-carboxymethyl-lysine (Nε-CML). Nε- CML was evaluated using receiver operating characteristic curve (ROC) curve analysis, and the area under curve (AUC) was determined. The mean levels of Nε-CML were 31.3 ± 21.2 ng/mL, 73.9 ± 35.0 ng/mL, 91.2 ± 66.7 ng/mL, and 132.0 ± 84.0 ng/mL in control, NoDR, NPDR, and PDR, respectively. On analysis of variance (ANOVA), the Ne-CML level was significantly different between the study groups (control, NoDR, NPDR, and PDR) (P < 0.001). Best-corrected visual acuity decreased with disease progression and increased levels of Ne-CML (P < 0.001). On AUC analysis, the following values were obtained NoDR = 0.67, NPDR = 0.69, and PDR = 0.84, showing that AGEs are the most sensitive biomarkers for PDR in DR. AGEs serve as biomolecular biomarkers for PDR and can indicate disease conversion from NPDR to PDR. They are new-age tools of translational medicine. |
| format | Article |
| id | doaj-art-2d67496a10e94070abb10d82deb847a3 |
| institution | Kabale University |
| issn | 0301-4738 1998-3689 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj-art-2d67496a10e94070abb10d82deb847a32025-08-20T03:29:45ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892025-06-0173690691110.4103/IJO.IJO_2115_24Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathyNibha MishraSandeep SaxenaRajendra K. ShuklaAnshul TiwariThe present study examines the role of advanced glycation end products (AGEs) as biomolecular biomarkers for proliferative diabetic retinopathy (PDR). A cross-sectional study with a total of 80 consecutive cases of type 2 diabetes mellitus (DM) was divided into no retinopathy (NoDR) (n = 20), non-proliferative diabetic retinopathy (NPDR) (n = 20), PDR (n = 20), and controls (n = 20). AGEs were assessed by assay of N-carboxymethyl-lysine (Nε-CML). Nε- CML was evaluated using receiver operating characteristic curve (ROC) curve analysis, and the area under curve (AUC) was determined. The mean levels of Nε-CML were 31.3 ± 21.2 ng/mL, 73.9 ± 35.0 ng/mL, 91.2 ± 66.7 ng/mL, and 132.0 ± 84.0 ng/mL in control, NoDR, NPDR, and PDR, respectively. On analysis of variance (ANOVA), the Ne-CML level was significantly different between the study groups (control, NoDR, NPDR, and PDR) (P < 0.001). Best-corrected visual acuity decreased with disease progression and increased levels of Ne-CML (P < 0.001). On AUC analysis, the following values were obtained NoDR = 0.67, NPDR = 0.69, and PDR = 0.84, showing that AGEs are the most sensitive biomarkers for PDR in DR. AGEs serve as biomolecular biomarkers for PDR and can indicate disease conversion from NPDR to PDR. They are new-age tools of translational medicine.https://journals.lww.com/10.4103/IJO.IJO_2115_24advanced glycation end productsbiomarkerdiabetes mellitusdiabetic retinopathynε – carboxymethyl lysine |
| spellingShingle | Nibha Mishra Sandeep Saxena Rajendra K. Shukla Anshul Tiwari Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy Indian Journal of Ophthalmology advanced glycation end products biomarker diabetes mellitus diabetic retinopathy nε – carboxymethyl lysine |
| title | Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| title_full | Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| title_fullStr | Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| title_full_unstemmed | Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| title_short | Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| title_sort | advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy |
| topic | advanced glycation end products biomarker diabetes mellitus diabetic retinopathy nε – carboxymethyl lysine |
| url | https://journals.lww.com/10.4103/IJO.IJO_2115_24 |
| work_keys_str_mv | AT nibhamishra advancedglycationendproductsarebiomolecularbiomarkersforproliferativediabeticretinopathy AT sandeepsaxena advancedglycationendproductsarebiomolecularbiomarkersforproliferativediabeticretinopathy AT rajendrakshukla advancedglycationendproductsarebiomolecularbiomarkersforproliferativediabeticretinopathy AT anshultiwari advancedglycationendproductsarebiomolecularbiomarkersforproliferativediabeticretinopathy |